Structural Insights into HCAR3-Ligand Recognition: Implications for Lipid Metabolism Research

Study Background and Research Question

Hydroxycarboxylic acid receptors (HCARs), notably HCAR2 (GPR109A) and HCAR3 (GPR109B), are G-protein coupled receptors (GPCRs) playing pivotal roles in human lipid metabolism and the regulation of metabolic disorders. As metabolite-sensing receptors, they are attractive targets for hypolipidemic agents and metabolic disorder research compounds. While HCAR2 activation is therapeutically beneficial, it is often associated with adverse effects such as cutaneous flushing. In contrast, HCAR3 represents a promising alternative due to its distinct pharmacological profile. However, the structural determinants governing ligand selectivity and function at HCAR3 have remained largely undefined. The reference study by Ye et al. (2025) directly addresses this gap by providing detailed structural insights into HCAR3-ligand complexes, with a particular focus on selective agonists such as Acifran ((R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid).

Key Innovation from the Reference Study

The central innovation of Ye et al. lies in their use of high-resolution cryo-electron microscopy (cryo-EM) to resolve the three-dimensional structures of HCAR3 in complex with multiple selective agonists: compound 6O, D-phenyllactic acid, IBC293, and Acifran. This structural elucidation provides, for the first time, a direct molecular view of how HCAR3 discriminates between ligands and reveals the features underpinning both recognition and selectivity. Notably, by comparing HCAR3 and HCAR2 bound to the same ligand, Acifran, the study pinpoints key amino acid residues and binding pocket geometries that explain why certain agonists preferentially activate HCAR3 without triggering HCAR2-related side effects.

Methods and Experimental Design Insights

The research team expressed HCAR3-Gi and HCAR2-Gi protein complexes in Sf9 insect cells, enabling the stabilization of receptor–G protein complexes necessary for structural analysis. They employed single-particle cryo-EM, achieving resolutions between 3.05 Å and 3.31 Å for HCAR3 bound to various ligands, and 2.72 Å for HCAR2-Acifran. Complementary functional assays, including cAMP inhibition studies in HEK-293 cells, validated the observed structural determinants by correlating them with receptor activation and ligand selectivity. Structural data were deposited in the Electron Microscopy Data Bank and atomic coordinates in the Protein Data Bank, ensuring transparency and reproducibility.

Protocol Parameters

• HCAR3/HCAR2-Gi complex expression: Transient transfection in Sf9 cells; optimize MOI and expression duration for maximal protein yield.
• Cryo-EM grid preparation: Rapid freezing in liquid ethane; grids imaged at <3.5 Å target resolution for structural analysis.
• Agonist binding assays: Use of 10–100 μM concentrations of selective agonists (including Acifran) for receptor-ligand complex formation prior to stabilization and imaging.
• Functional validation: cAMP inhibition measured in HEK-293 cells transfected with HCAR3 or HCAR2; assess EC50 and maximal inhibition for each ligand.
• Binding pocket mutagenesis: Site-directed mutagenesis at key pocket residues (e.g., F1073.32, V/L832.60, Y/N862.63, S/W9123.48) to validate their roles in ligand selectivity and response.

These parameters reflect both the reference study and common protocols for GPCR structural and functional analysis.

Core Findings and Why They Matter

The cryo-EM structures reveal that ligand affinity and selectivity at HCAR3 are dictated by both the occupation of the orthosteric binding pocket and the interactions with specific amino acids. For example, compound 6O's high affinity to HCAR3 is attributed to its ability to fully occupy both R1 and R2 regions within the binding site. In the case of Acifran, the study shows that π–π interactions with F1073.32, as well as differences in the size and composition of the ligand-binding pocket (notably at V/L832.60, Y/N862.63, and S/W9123.48), create a selectivity filter between HCAR3 and HCAR2. This provides a structural rationale for designing hypolipidemic agents that target lipid metabolism regulation with reduced risk of HCAR2-mediated side effects, a key advance for metabolic disorder research compounds.

Functionally, these discoveries explain why some ligands, such as Acifran, can act as selective HCAR3 agonists, modulating lipid signaling pathway activity without triggering the unwanted flushing response seen with HCAR2 activation. This opens avenues for rational drug design aimed at developing next-generation hypolipidemic agents with improved specificity and safety profiles, enhancing the translational potential for metabolic disease therapy.

Comparison with Existing Internal Articles

Several internal resources have previously highlighted Acifran’s value as a selective HM74A/GPR109A and GPR109B agonist for lipid metabolism research. For example, Acifran: Precision HM74A/GPR109A Agonist for Lipid Metabo... emphasizes Acifran’s specificity for interrogating lipid signaling pathways in metabolic disorder models. The current study by Ye et al. extends this narrative by providing the structural underpinnings for that selectivity, directly visualizing the receptor-ligand interface and confirming the molecular determinants previously hypothesized in the literature.

Similarly, the Structural Mechanisms of HCAR3 Agonist Selectivity Revealed by Cryo-EM article contextualizes the importance of cryo-EM in understanding ligand recognition. The new reference work delivers the atomic-level details that were previously lacking, enabling more precise modulation of lipid metabolism regulation in both basic and translational research settings.

Limitations and Transferability

Despite the depth of structural insight, several limitations are acknowledged. The study focuses primarily on in vitro structural and functional assays; in vivo pharmacological data are not provided, and thus the physiological relevance or translatability of these findings to clinical settings requires further exploration. The ligand panel, while representative, does not capture the full chemical diversity of potential HCAR3 modulators. Furthermore, while the study delineates selectivity mechanisms for HCAR3 over HCAR2, it does not address off-target effects on other GPCRs or long-term receptor desensitization phenomena.

Nonetheless, the direct structural evidence provided by Ye et al. offers a robust foundation for rational ligand design and preclinical compound screening, particularly for those developing metabolic disorder research compounds targeting lipid metabolism regulation. Transferability to other receptor systems, or to in vivo disease models, will depend on future pharmacological validation.

Research Support Resources

For researchers aiming to translate these structural findings into actionable workflows, high-purity selective agonists are essential. Acifran (SKU B6848), with its defined activity as an HM74A/GPR109A and GPR109B agonist, is suitable for detailed studies of receptor-ligand interactions and lipid signaling pathway modulation, as supported by both the reference study and internal benchmarking. For protocol optimization, consult published structural and functional studies to align assay parameters with experimental objectives. APExBIO provides compound-specific information and technical support for integrating Acifran into lipid metabolism research workflows.